Dendrimers have long been one of our favourite areas of nanotechnology. Not just because one of our staff has a PhD on Amphiphillic Dendrimers but because of their flexibility and range of applications exceed that of carbon nanotubes.
Now we have been joined by Aurora Funds, who just led a $6 million investment in Hyperbranch Medical Technology, and the apparently premature news that Dow Chemical are transferring their considerable know how into Starpharma’s Dendritic Nanotechnologies unit in exchange for a 31% equity holding.
Starpharma were not too happy about the publication of this information and immediately requested the Australian Stock Exchange to halt trading in the Companys securities.
Expect a ‘proper’ announcement later this week.